{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:02:44Z","timestamp":1790136164753,"version":"4.0.1"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Cefoxitin could be an alternative to carbapenems in extended-spectrum-beta-lactamase-producing\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            (ESBL-EC) infections. However, pharmacological and clinical data regarding cefoxitin are limited. Using a recent pharmacological model and the MICs of ESBL-EC collected from pyelonephritis, we determined the probabilities to reach four pharmacological targets: free cefoxitin concentrations above the MIC during 50% and 100% of the administration interval (T&gt;MIC = 50% and T&gt;MIC = 100%, respectively) and free cefoxitin concentrations above 4\u00d7 MIC during 50% and 100% of the administration interval (T&gt;4MIC = 50% and T&gt;4MIC = 100%, respectively). Cefoxitin could be used to treat ESBL-EC pyelonephritis, but administration modalities should be optimized according to MICs in order to reach pharmacological targets.\n          <\/jats:p>","DOI":"10.1128\/aac.02509-14","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T06:59:24Z","timestamp":1398754764000},"page":"4899-4901","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacological Study of Cefoxitin as an Alternative Antibiotic Therapy to Carbapenems in Treatment of Urinary Tract Infections Due to Extended-Spectrum-\u03b2-Lactamase-Producing Escherichia coli"],"prefix":"10.1128","volume":"58","author":[{"given":"H.","family":"Guet-Revillet","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de Microbiologie\u2014Hygi\u00e8ne Hospitali\u00e8re, H\u00f4pital Necker-Enfants-Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Emirian","sequence":"additional","affiliation":[{"name":"Service de Bact\u00e9riologie, Virologie, Hygi\u00e8ne, H\u00f4pital Henri-Mondor, AP-HP, Cr\u00e9teil, France"},{"name":"Universit\u00e9 Paris-Est, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Groh","sequence":"additional","affiliation":[{"name":"Service de Microbiologie\u2014Hygi\u00e8ne Hospitali\u00e8re, H\u00f4pital Necker-Enfants-Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nebbad-Lechani","sequence":"additional","affiliation":[{"name":"Service de Bact\u00e9riologie, Virologie, Hygi\u00e8ne, H\u00f4pital Henri-Mondor, AP-HP, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Service de Microbiologie\u2014Hygi\u00e8ne Hospitali\u00e8re, H\u00f4pital Necker-Enfants-Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Join-Lambert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de Microbiologie\u2014Hygi\u00e8ne Hospitali\u00e8re, H\u00f4pital Necker-Enfants-Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bille","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de Microbiologie\u2014Hygi\u00e8ne Hospitali\u00e8re, H\u00f4pital Necker-Enfants-Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jullien","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie Clinique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Paris, France"},{"name":"INSERM U1129, Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Zahar","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de Microbiologie\u2014Hygi\u00e8ne Hospitali\u00e8re, H\u00f4pital Necker-Enfants-Malades, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis942"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2012.03.035"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110655"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2012.01.004"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06233-11"},{"key":"e_1_3_1_9_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2012","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST, Basel, Switzerland. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_2.0_120221.pdf."},{"key":"e_1_3_1_10_2","volume-title":"EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2013","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. EUCAST, Basel, Switzerland. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Resistance_mechanisms\/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf."},{"key":"e_1_3_1_11_2","volume-title":"Recommandations 2012","author":"Comit\u00e9 de l'Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie","year":"2012","unstructured":"Comit\u00e9 de l'Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. 2012. Recommandations 2012. Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie, Paris, France. http:\/\/www.sfm-microbiologie.org\/."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1206-1"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.560"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2013.01.006"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.933-951.2001"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.5.1005"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.342"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.13867"},{"key":"e_1_3_1_19_2","first-page":"129","article-title":"Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia","volume":"42","author":"Palasubramaniam S","year":"2009","unstructured":"PalasubramaniamSMuniandySNavaratnamP. 2009. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia. J. Microbiol. Immunol. Infect. 42:129\u2013133.","journal-title":"J. Microbiol. Immunol. Infect."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02509-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02509-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:55:01Z","timestamp":1645484101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02509-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1128\/AAC.02509-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02509-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"2014-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}